Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) EBIT (2018 - 2025)

Historic EBIT for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$16.5 million.

  • Arcturus Therapeutics Holdings' EBIT fell 5378.6% to -$16.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$78.3 million, marking a year-over-year increase of 273.01%. This contributed to the annual value of -$95.7 million for FY2024, which is 2233.11% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' EBIT stood at -$16.5 million, which was down 5378.6% from -$11.6 million recorded in Q2 2025.
  • Over the past 5 years, Arcturus Therapeutics Holdings' EBIT peaked at $121.5 million during Q4 2022, and registered a low of -$57.7 million during Q1 2021.
  • For the 5-year period, Arcturus Therapeutics Holdings' EBIT averaged around -$21.6 million, with its median value being -$22.1 million (2022).
  • In the last 5 years, Arcturus Therapeutics Holdings' EBIT plummeted by 50944.83% in 2021 and then soared by 42262.45% in 2022.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' EBIT stood at -$37.6 million in 2021, then skyrocketed by 422.62% to $121.5 million in 2022, then plummeted by 115.04% to -$18.3 million in 2023, then plummeted by 82.76% to -$33.4 million in 2024, then skyrocketed by 50.55% to -$16.5 million in 2025.
  • Its EBIT was -$16.5 million in Q3 2025, compared to -$11.6 million in Q2 2025 and -$16.8 million in Q1 2025.